Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 69 EV-to-EBITDA is 12.15 as of Jul. 25, 2026, which is 20% above its 10-year median of 10.09. GuruFocus rates XSWX:BIIB with a GF Score™ of 69/100 and a GF Value™ of CHF164.93. The stock has 7 warning signs investors should review. Among 742 Drug Manufacturers companies, Biogen ranks better than 53.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biogen's enterprise value is CHF26,250 Mil.
Biogen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2,161 Mil. Therefore, Biogen's EV-to-EBITDA for today is 12.15.
The historical rank and industry rank for Biogen's EV-to-EBITDA or its related term are showing as below:
XSWX:BIIB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.43 Med: 10.09 Max: 21.54
Current: 11.9
During the past 13 years, the highest EV-to-EBITDA of Biogen was 21.54. The lowest was 5.43. And the median was 10.09.
XSWX:BIIB's EV-to-EBITDA is ranked better than 53.1% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs XSWX:BIIB: 11.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-25), Biogen's stock price is CHF173.46.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF7.475. Therefore, Biogen's PE Ratio (TTM) for today is 23.21.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Biogen (XSWX:BIIB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biogen's share price for today is CHF173.46.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF7.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biogen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BIIB vs OGN, AMRN, SCLX: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Biogen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biogen's EV-to-EBITDA falls into.
Biogen's current Enterprise Value is CHF26,250 Mil.
Biogen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,161 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (XSWX:BIIB) has a EV-to-EBITDA of 12.15 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biogen. This is 20% above median its historical median of 10.09. Over the past decade, Biogen's EV-to-EBITDA has ranged from 5.43 to 21.54. According to the industry distribution chart, Biogen ranks #348 out of 742 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Biogen's EV-to-EBITDA too high?
Biogen's current EV-to-EBITDA of 12.15 is 20% above median its 10-year median of 10.09. Over the past 10 years, this metric has ranged from a low of 5.43 to a high of 21.54. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Biogen's value of 12.15 is 6.3% below this industry median. Based on the distribution chart, Biogen ranks #348 out of 742 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogen has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's EV-to-EBITDA compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #348 out of 742 companies for EV-to-EBITDA. This puts Biogen in the upper half of its industry. The industry median EV-to-EBITDA is 12.96. Biogen's value of 12.15 is 6.3% below this benchmark. Historically, Biogen's own EV-to-EBITDA has ranged from 5.43 to 21.54 over the past decade. While the company's 10-year median is 10.09 vs. the industry median of 12.96, Biogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current EV-to-EBITDA of 12.15 is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biogen. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current EV-to-EBITDA is 12.15, which is 20% above median its own 10-year median of 10.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current EV-to-EBITDA of 12.15. The stock's GF Value™ is CHF164.93, compared to a current price of CHF173.46 — trading 5.2% above its estimated fair value. The current EV-to-EBITDA is 12.15, which is 20% above median its 10-year median of 10.09 and 6.3% below the Drug Manufacturers industry median of 12.96. Biogen's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current EV-to-EBITDA is 12.15 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 5.2% above its estimated GF Value™ of CHF164.93.
Key valuation signals for XSWX:BIIB:
EV-to-EBITDA: 12.15 (20% above median its 10-year median of 10.09)
GF Value™: CHF164.93 vs. price of CHF173.46 (5.2% above fair value)
Industry Position: 6.3% below the Drug Manufacturers median (#348 of 742)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
69GF Score
Get the complete analysis for XSWX:BIIB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
